Milestone Pharmaceuticals Valuation
| MIST Stock | USD 1.72 0.10 5.49% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Milestone Pharmaceuticals secures a last-minute Real Value of $2.94 per share. The latest price of the firm is $1.72. Our model forecasts the value of Milestone Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 130.06 M, shares owned by insiders of 3.31 %, and Return On Equity of -2.61 as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Milestone Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Milestone Pharmaceuticals is based on 3 months time horizon. Increasing Milestone Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Milestone Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 1.72, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.72 | Real 2.94 | Hype 1.73 |
The intrinsic value of Milestone Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Milestone Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Milestone Pharmaceuticals helps investors to forecast how Milestone stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Milestone Pharmaceuticals more accurately as focusing exclusively on Milestone Pharmaceuticals' fundamentals will not take into account other important factors: About Milestone Pharmaceuticals Valuation
The stock valuation mechanism determines Milestone Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Milestone Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Milestone Pharmaceuticals. We calculate exposure to Milestone Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Milestone Pharmaceuticals's related companies.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company was incorporated in 2003 and is headquartered in Montral, Canada. Milestone Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.